Quest Partners LLC Buys 4,692 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Quest Partners LLC boosted its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 344.0% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 6,056 shares of the company’s stock after purchasing an additional 4,692 shares during the quarter. Quest Partners LLC’s holdings in Viridian Therapeutics were worth $79,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Vestal Point Capital LP purchased a new stake in Viridian Therapeutics in the fourth quarter valued at about $21,780,000. Perceptive Advisors LLC increased its holdings in shares of Viridian Therapeutics by 71.1% during the fourth quarter. Perceptive Advisors LLC now owns 1,730,212 shares of the company’s stock valued at $37,684,000 after acquiring an additional 719,007 shares in the last quarter. RTW Investments LP purchased a new position in shares of Viridian Therapeutics in the 4th quarter valued at approximately $13,195,000. Candriam S.C.A. boosted its stake in Viridian Therapeutics by 167.8% in the 2nd quarter. Candriam S.C.A. now owns 749,804 shares of the company’s stock worth $9,754,000 after purchasing an additional 469,804 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in Viridian Therapeutics by 7.8% during the 1st quarter. Vanguard Group Inc. now owns 3,234,279 shares of the company’s stock worth $56,632,000 after purchasing an additional 233,331 shares during the last quarter.

Insider Buying and Selling at Viridian Therapeutics

In related news, Director Fairmount Funds Management Llc purchased 1,600,000 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The stock was bought at an average price of $18.75 per share, with a total value of $30,000,000.00. Following the acquisition, the director now owns 3,445,813 shares in the company, valued at $64,608,993.75. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.65% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

VRDN has been the subject of a number of research analyst reports. The Goldman Sachs Group raised their price target on shares of Viridian Therapeutics from $25.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, September 12th. BTIG Research lifted their price target on Viridian Therapeutics from $46.00 to $56.00 and gave the stock a “buy” rating in a research report on Tuesday, September 10th. Royal Bank of Canada increased their price objective on Viridian Therapeutics from $35.00 to $44.00 and gave the company an “outperform” rating in a report on Friday, September 13th. Oppenheimer reaffirmed an “outperform” rating and set a $28.00 target price (down previously from $31.00) on shares of Viridian Therapeutics in a report on Monday, August 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $27.00 price target on shares of Viridian Therapeutics in a report on Tuesday, September 10th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $35.30.

Viridian Therapeutics Stock Performance

Shares of NASDAQ VRDN opened at $21.18 on Wednesday. The company has a market capitalization of $1.35 billion, a PE ratio of -4.71 and a beta of 1.03. The company has a debt-to-equity ratio of 0.05, a quick ratio of 15.82 and a current ratio of 15.82. The company’s fifty day moving average price is $15.75 and its 200 day moving average price is $15.01. Viridian Therapeutics, Inc. has a 1 year low of $10.93 and a 1 year high of $24.18.

Viridian Therapeutics (NASDAQ:VRDN) last posted its earnings results on Thursday, August 8th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.15). Viridian Therapeutics had a negative return on equity of 83.18% and a negative net margin of 79,185.77%. The firm had revenue of $0.07 million for the quarter, compared to analysts’ expectations of $0.09 million. On average, research analysts predict that Viridian Therapeutics, Inc. will post -3.93 earnings per share for the current year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.